FDA launches Elsa, an AI tool designed to accelerate agencywide operations — Jun 3rd, 2025

[FDA headquarters in Washington DC.] JHVEPhoto The U.S. Food and Drug Administration (FDA) has launched Elsa, an AI tool designed to modernize and speed up agency-wide operations ranging from scientific reviews to investigations. Marty Makary, the head of the agency, announced the launch...

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio — May 27th, 2025

- Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab suniri...

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV — May 21st, 2025

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible l...

Key Drivers Behind AbbVie’s (ABBV) Performance — May 23rd, 2025

RS Investments, an investment management company, released its “RS Large Cap Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its benchmark, the Russell 1000 Value Index (the “Index”),...

AbbVie (ABBV) has a Stable and Highly Profitable Business Model — May 22nd, 2025

Renaissance Investment Management, an investment management company, released its Q1 2025 “Large Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The S&P 500 experienced a 4.3% loss in Q1 due to uncertainty in technology stock valuations and US economi...

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals — Jun 3rd, 2025

The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVi...

The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie — May 19th, 2025

For Immediate Release Chicago, IL – May 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog incl...

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer — May 15th, 2025

AbbVie ABBV announced that the FDA has granted accelerated approval to its antibody-drug conjugate (ADC), telisotuzumab vedotin (or Teliso-V), for treating certain patients with non-small cell lung cancer (NSCLC). The drug will be marketed under the brand name Emrelis. Under this approval...

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference — Jun 3rd, 2025

NORTH CHICAGO, Ill., June 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025. Management will participate in a fireside chat at 10:20 a.m. Central time. A live audio webcast of the presentati...

ABBV Quantitative Stock Analysis — Jun 3rd, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momen...

AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers — May 28th, 2025

AbbVie recently unveiled promising data on its investigational therapies, including the novel c-Met-targeting ADC, Temab-A, and the SEZ6-directed ADC, ABBV-706, indicating progress in their clinical pipelines. Despite these announcements, AbbVie's stock price remained flat, aligned with ov...

Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings — May 16th, 2025

AbbVie Inc.'s (NYSE:ABBV) stock was strong despite it releasing a soft earnings report last week. We think that investors might be looking at some positive factors beyond the earnings numbers. This technology could replace computers: discover the 20 stocks are working to make quantum comp...

Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play — May 22nd, 2025

Investing.com-- French pharmaceutical giant Sanofi SA (EPA:SASY) said on Wednesday it had entered an agreement to buy U.S.-listed biotech firm Vigil Neuroscience Inc (NASDAQ:VIGL), with focus chiefly on an early-stage Alzheimer’s drug being developed by the firm. Sanofi will pay $8 in...

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact Levi & Korsinsky — May 30th, 2025

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses — May 14th, 2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and...

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 — May 27th, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disord...

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases — May 14th, 2025

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE)...

Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock” — May 16th, 2025

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how about one of my absolute favorites right here too, AbbVie. Now here's a drug company with no patent cliff in sight whatsoever. Got tremendous franchises in ne...

AbbVie Inc. (ABBV): Among the Best Dividend Growth Stocks with High Yields — May 14th, 2025

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend growth stocks. Dividend-paying stocks have been gaining popularity among investors due to t...

Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc. (ABBV) of a Class Action Lawsuit and an Upcoming Deadline — May 22nd, 2025

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit — May 23rd, 2025

AbbVie Inc. (NYSE:ABBV) has achieved a significant legal victory as the Illinois Appellate Court upheld the dismissal of a shareholder class action lawsuit stemming from its $63 billion acquisition of Allergan plc in 2020.AbbVie Inc. (NYSE:ABBV) Scores Major Legal Victory as Illinois Court...

Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut. — May 18th, 2025

Key Points AbbVie's earnings are down nearly 70% since its pandemic highs. Medtronic has increased its dividend for 47 consecutive years. Pfizer has an outsized dividend yield of 7.5% that's potentially unsustainable. 10 stocks we like better than Pfizer › Dividend stocks can be a smar...

2 Incredible Dividend Growth Stocks to Buy Now — May 21st, 2025

Key Points Dividend growth stocks often deliver returns that are superior to the benchmark S&P 500. AbbVie and W.W. Grainger are elite dividend growth stocks that would be solid additions to any income-focused portfolio. 10 stocks we like better than AbbVie › Dividend growth stocks hav...

1 Healthcare Stock to Keep an Eye On and 2 to Ignore — May 16th, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks ...

US FDA approves AbbVie's drug for a type of lung cancer — May 14th, 2025

(Reuters) -The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday. The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, w...

AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit — May 23rd, 2025

AbbVie Inc. (NYSE:ABBV) has achieved a significant legal victory as the Illinois Appellate Court upheld the dismissal of a shareholder class action lawsuit stemming from its $63 billion acquisition of Allergan plc in 2020.AbbVie Inc. (NYSE:ABBV) Scores Major Legal Victory as Illinois Court...

The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands — May 30th, 2025

For Immediate Release Chicago, IL – May 30, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog incl...

AbbVie Partners with Chicago Cubs on "Striking Out Cancer" — May 30th, 2025

Chicago-based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill., May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer...

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? — May 28th, 2025

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this drugmaker have returned -4%, compared to the Zacks S&P 500 composi...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc. (ABBV) Shareholders — May 19th, 2025

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV — May 16th, 2025

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

Guru Fundamental Report for ABBV — Jun 1st, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momen...

The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV — May 15th, 2025

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible l...

3 Value Stocks Facing Headwinds — May 22nd, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great de...

Pfizer Signs Experimental Drug Licensing Agreement With 3SBio — May 20th, 2025

Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707. According to the deal, Pfizer will pay $1.25 billion upfront and could pay up to an additional $4.8 billion contingent upon achieving certain...

Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals — May 16th, 2025

This week, Bayer BAYRY announced first-quarter 2025 results. Novo Nordisk NVO and GSK plc GSK announced licensing deals with smaller biotechs. The FDA granted approval to Merck’s MRK drug, Welireg, for its third indication in the United States and AbbVie’s ABBV Emrelis, its first inter...

Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck. — May 14th, 2025

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next. Continue Reading View Comments...

AbbVie (ABBV) Soared on Favorable Tailwinds — May 20th, 2025

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.  The S&P 500 Index ended Q1 down 4.3%, marking a turbulent start to 2025. The volatility that ...

U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression — May 14th, 2025

– EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited treatment options – Lung cancer remains the leading cause of cancer-related deaths throughout the worl...

AbbVie (ABBV) Gains As Market Dips: What You Should Know — May 30th, 2025

In the latest trading session, AbbVie (ABBV) closed at $186.11, marking a +0.26% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.01%. Elsewhere, the Dow saw an upswing of 0.13%, while the tech-heavy Nasdaq depreciated by 0.32%. Coming into today,...

High Growth Tech Stocks To Watch In The US June 2025 — Jun 3rd, 2025

Over the last 7 days, the United States market has risen by 2.0% and is up 12% over the past year, with earnings forecasted to grow by 14% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potentia...

AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel — May 22nd, 2025

AbbVie experienced a 6.8% share price increase over the past month, coinciding with several significant corporate events. The company announced a collaboration with ADARx Pharmaceuticals to develop siRNA therapeutics, as well as FDA approval for EMRELIS™ in treating lung cancer, indicati...

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses — May 14th, 2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and...

AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat — May 29th, 2025

AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective res...

Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play — May 22nd, 2025

Investing.com-- French pharmaceutical giant Sanofi SA (EPA:SASY) said on Wednesday it had entered an agreement to buy U.S.-listed biotech firm Vigil Neuroscience Inc (NASDAQ:VIGL), with focus chiefly on an early-stage Alzheimer’s drug being developed by the firm. Sanofi will pay $8 in...

AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient — May 22nd, 2025

Following a national competition, AbbVie and SpinUp – the University of Toronto's lab-based, life sciences accelerator – announce Neuropeutics Inc as recipient of first AbbVie Biotech Innovators Award Neuropeutics Inc receives a year of laboratory space and equipment at no cost, as we...

1 Healthcare Stock to Keep an Eye On and 2 to Ignore — May 16th, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks ...

AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas — May 14th, 2025

- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies across neuroscience, immunology and oncology NORTH CHICAGO, Ill. and SAN DIEGO, May 14, 2025 ...

Top 15 investment grade bond issuers — Jun 1st, 2025

[A man examines the inscription Bonds with a magnifying glass. Assessment of the value and profitability of securities. Investment. Terms and conditions. Face value. Raise money to finance new projects] Andrii Yalanskyi/iStock via Getty Images Investment grade credit (NYSEARCA:LQD [https:...

3 Value Stocks Facing Headwinds — May 22nd, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great de...